AMA adopts policy aimed to bolster transparency of prescription costs

| 4 Min Read

As prescription drug prices have spiked — often without reason — the American Medical Association (AMA) has advocated for more transparency in pricing to protect patients. At its Annual Meeting today, the AMA adopted several policies, including policies on direct-to-consumer ads and naloxone pricing that aim to give patients more information about drugs prescribed to them and shed light on the rationale for price increases.

“Taken together, these policies would bring much needed transparency to drug pricing and provide a clear benefit to consumers struggling with exorbitant costs. There seems to be no logic — or warning — to these price spikes. In the case of naloxone, communities are struggling to afford a life-saving treatment. Sunlight is needed to help respond to price shifts, because if the pricing trends continue, patients and communities will not be able to afford life-saving drugs,” said AMA President-elect Barbara L. McAneny, M.D..

Full press release available when you sign in

Sign in to the AMA website to get the full version of this press release. 

AMA membership has its advantages

  • Be a part of the nation's largest physician organization
  • Play a role in shaping the future of health care
  • Enjoy exclusive perks and savings

Not a member? Become a member now.

 

FEATURED STORIES

Man power walking or jogging, with dumbbells

New changes expand diabetes-prevention for more Medicare patients

| 3 Min Read
Three healthcare workers in discussion

AMA Joy in Medicine points the way to better care

| 5 Min Read
Doctors hold up magnifying glasses over a giant pancreas

Beyond watch and wait: Taking aim at pancreatic cysts

| 7 Min Read
Philip Kuriakose, MD, featured on "Health vs. Hype" AMA podcast

5 things patients should know about microplastics

| 8 Min Read